But mixed data and a previous failure provide reasons to be cautious.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Despite widespread failures biopharma presses on in Alzheimer's, with approaches including BACE and Tau inhibition.